Generate Biomedicines, Inc. (GENB) vs Novavax, Inc. (NVAX)
A side-by-side comparison of Generate Biomedicines, Inc. and Novavax, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GENB
Generate Biomedicines, Inc.
$13.93HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
NVAX
Novavax, Inc.
$11.25HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — GENB vs NVAX
growth of $100 · dividends reinvested · last 1yGENB +10.0% (+10.0%/yr)NVAX +31.8% (+31.8%/yr)NVAX compounded faster over this window
GENB NVAX
GENB vs NVAX: by the numbers
- •NVAX is the larger company ($1.85B vs $1.79B market cap).
- •Both run net losses; NVAX's is the smaller (-59.87% vs -636.99% net margin).
Metrics side by side
Valuation
| Metric | GENB | NVAX |
|---|---|---|
| P/S ratio | N/A | 4.47 |
| P/B ratio | 3.92 | N/A |
Profitability
| Metric | GENB | NVAX |
|---|---|---|
| Gross margin | 100.00% | 93.67% |
| Operating margin | -737.04% | 50.14% |
| Net margin | -636.99% | -59.87% |
| ROIC | -94.79% | -36.37% |
Growth (annualized)
| Metric | GENB | NVAX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 118.86% |
| Total return CAGR (5Y) | N/A | -40.61% |
Go deeper
Dig into the metrics
Generate Biomedicines ROENovavax ROEGenerate Biomedicines operating marginNovavax operating marginGenerate Biomedicines revenue growthNovavax revenue growthGenerate Biomedicines free cash flowNovavax free cash flow
Generate Biomedicines & Novavax appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.